Ramazan ACAR, Murat YILDIRIM

Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences

Hodgkin Lymphoma (HL) is one of the hematological malignancies where the inflammatory process is quite high, immunotherapy agents are frequently used and successful results are obtained. We aimed to show real-life data on health outcomes in adult patients withrecurrent or refractory HL who received nivolumab (immune checkpoint inhibitory). We analyzed the data of 15 patients who received nivolumab after or before high dose chemotherapy (HDCT) for relapsed or refractory HL from 2010 to 2020. Overall response rate (ORR), overall survival (OS) and progression-free survival (PFS) of the patients were evaluated. 15 patients were observed in this study. The mean age of the study group was 26.9 ±10.9 years. 40% of the patients were female (n=6). Overall response rate (ORR) was 80 %. The median overall survival (OS) and progression-free survival (PFS) were 50.7 months (95% CI: 37.2-64.2) and 46.2 months (95% CI: 32.9-59.5), respectively. 1-year OS and PFS rates were 90.9% and %88.2, respectively. 5-year OS rate was 67.3%. Nivolumab treatment is a safe, effective and excellent treatment option for relapsed or refractory adult HL patients with a good ORR, OS and PFS time.

PDF

___

1. Kansara R, Speziali C. Immunotherapy in hematologic malignancies. Curr Oncol. 2020;27:124.

2. Von Tresckow B, Müller H, Eichenauer et al. Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant. Leukem lymphom. 2014;55:1922-4.

3. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood, J American Societ Hematol. 2010;116:3268-77.

4. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New England J Med. 2015;372:311-9.

5. Armand P, Engert A, Younes A et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clinic Oncol. 2018;36:1428.

6. Eich HT, Diehl V, Görgen H et al. Intensified chemotherapy and dosereduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clinic Oncol. 2010;28:4199-206.

7. Martin N, Borchiellini D, Coso D et al. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poorprognosis lymphoma. Leukem lymphom. 2015;56:2379-87.

8. Chen R, Zinzani PL, Lee HJ et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134:1144-53.

9. Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New England J Med. 2017;377:1345-56.

10. Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. New England J Med. 2016;375:1823-33.

11. Diefenbach CS, Hong F, David KA et al. A phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). American Soci Hematol. 2020;7:660-70.